Noteworthy

Oct 01, 2010
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Innovating in R&D may not be such a complicated task. Consumers simply want to find the product that gets a job done right every time
Oct 01, 2010
Pharmaceutical Executive
Ethical behavior can be a bridge-builder in an era where Big Pharma needs to find new partners. Is it up to the challenge?
Oct 01, 2010
Pharmaceutical Executive
Will Roche's precedent push the regulatory community to create standards that will level the playing field for all contenders?
Oct 01, 2010
Pharmaceutical Executive
Tracking, monitoring, and trend evaluation is not enough. Companies must now do more than assess what happened and why.
Sep 01, 2010
Pharmaceutical Executive
Professor Bill Trombetta takes a snapshot of the "Glamour 24" companies shaping the pharma industry this year and beyond
Sep 01, 2010
Pharmaceutical Executive
Pfizer's VP and Assistant General Counsel for Global Patents and Policy, Roy Waldron, discusses its collaborative strategy to refresh the face of IP
Sep 01, 2010
Pharmaceutical Executive
A new leader, a big acquisition, and a bold investment in HIV may all be in the works at Gilead. But what will it take to restore the glory days?
Jul 01, 2010
Pharmaceutical Executive
Pharma companies are starting to get back in the game with increased advertising spend in 2009. Do we have economic recovery to thank, or is there a deeper cause?
Jul 01, 2010
Pharmaceutical Executive
Outsourcing the sales representative function can help pharmaceutical companies build on their bottom line.
Jul 01, 2010
Pharmaceutical Executive
FDA's risk-reduction requirements could be the bridge to a bright new future for the pharma industry.
native1_300x100
lorem ipsum